RJA
JNCE

Raymond James & Associates’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Raymond James & Associates’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-48,254
Closed -$394K – 3912
2020
Q3 		$394K Buy
48,254
+34,203
+243% +$212K ﹤0.01% 2791
2020
Q2 		$97K Buy
14,051
+1,119
+9% +$6.04K ﹤0.01% 3288
2020
Q1 		$61K Buy
+12,932
New +$74.4K ﹤0.01% 3295
2019
Q1 		– Sell
-20,961
Closed -$71K – 3742
2018
Q4 		$71K Buy
+20,961
New +$97.9K ﹤0.01% 3352

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Raymond James & Associates's JNCE Position: Q4 2020 in Review

Raymond James & Associates sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2020, closing a stake of 48,254 shares — an estimated $394K sold.

Raymond James & Associates first reported a position in JNCE in Q4 2018 and held it in 4 quarters. The position peaked at $394K in Q3 2020. 104 funds tracked by Wall St. Rank hold JNCE as of Q4 2020.

  • Raymond James & Associates reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Raymond James & Associates sold 48,254 Jounce Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $394K.
  • Raymond James & Associates first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
  • Raymond James & Associates's Jounce Therapeutics, Inc. Common Stock position peaked at $394K in Q3 2020.
  • 104 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Raymond James & Associates's 13F filing for Q4 2020, filed 12 Feb 2021.